There was a fresh warning about cyber security in digital health this week after anti-virus firm McAfee proved that hackers could break into patients’ medical devices and alter their vital
Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reporte
